Evidence map›Paper›PMID 27409614›Full record

ArticleInternational journal of molecular sciences2016

Neuroprotective Effect of Puerarin on Glutamate-Induced Cytotoxicity in Differentiated Y-79 Cells via Inhibition of ROS Generation and Ca(2+) Influx.

Ke Wang, Xue Zhu, Kai Zhang, Zhifeng Wu, Song Sun, Fanfan Zhou, Ling Zhu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Molecular Mechanisms Underlying the Pathogenicity ofMedicina (Kaunas, Lithuania) · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Puerarin Inhibits Endothelium-Dependent Contractions in Mouse Carotid Arteries.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ke WangKey Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China. wangke@jsinm.org.
Xue ZhuKey Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China. zhuxue@jsinm.org.
Kai ZhangKey Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China. zhangkai@jsinm.org.
Zhifeng WuDepartment of Ophthalmology, Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi 214002, China. wuzhifeng248@gmail.com.
Song SunDepartment of Ophthalmology, Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi 214002, China. sunsong813@gmail.com.
Fanfan ZhouFaculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia. fanfan.zhou@sydney.edu.au.
Ling ZhuSave Sight Institute, University of Sydney, Sydney, NSW 2000, Australia. ling.zhu@sydney.edu.au.
University of Sydney · AUWuxi No.2 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutamate toxicity is estimated to be the key cause of photoreceptor degeneration in the pathogenesis of retinal degenerative diseases. Oxidative stress and Ca(2+) influx induced by glutamate are responsible for the apoptosis process of photoreceptor degeneration. Puerarin, a primary component of Kudzu root, has been widely used in the clinical treatment of retinal degenerative diseases in China for decades; however, the detailed molecular mechanism underlying this effect remains unclear. In this study, the neuroprotective effect of puerarin against glutamate-induced cytotoxicity in the differentiated Y-79 cells was first investigated through cytotoxicity assay. Then the molecular mechanism of this effect regarding anti-oxidative stress and Ca(2+) hemostasis was further explored with indirect immunofluorescence, flow cytometric analysis and western blot analysis. Our study showed that glutamate induced cell viability loss, excessive reactive oxygen species (ROS) generation, calcium overload and up-regulated cell apoptosis in differentiated Y-79 cells, which effect was significantly attenuated with the pre-treatment of puerarin in a dose-dependent manner. Furthermore, our data indicated that the neuroprotective effect of puerarin was potentially mediated through the inhibition of glutamate-induced activation of mitochondrial-dependent signaling pathway and calmodulin-dependent protein kinase II (CaMKII)-dependent apoptosis signal-regulating kinase 1(ASK-1)/c-Jun N-terminal kinase (JNK)/p38 signaling pathway. The present study supports the notion that puerarin may be a promising neuroprotective agent in the prevention of retinal degenerative diseases.

Indexed as

ApoptosisCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2Caspase 3Cell Line, TumorCell SurvivalCytochromes cGlutamic AcidHumansIsoflavonesJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase Kinase 5Membrane Potential, MitochondrialNeuroprotective Agentsp38 Mitogen-Activated Protein KinasesReactive Oxygen SpeciesCalciumCalcium-Calmodulin-Dependent Protein Kinase Type 2Caspase 3Cytochromes cGlutamic AcidIsoflavonesJNK Mitogen-Activated Protein KinasesMAP Kinase Kinase Kinase 5Neuroprotective Agentsp38 Mitogen-Activated Protein KinasespuerarinReactive Oxygen Speciesglutamate toxicitypuerarinretinal degenerative diseasesY-79 cells

Identifiers

PMID27409614
PMCPMC4964484
OpenAlexW2467409959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.